Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

By C. Wanner, Silvio E. Inzucchi, J. Lachin, D. Fitchett, M. von Eynatten, M. Mattheus, O. Johansen, Hans J Woerle, U. Broedl, B. Zinman. New England Journal of Medicine, 2016

3,043 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/508b0daf6c74ba96dda7ddbaf04b0b4b7f8d97f5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Nur Samsu

In Surgery

1. Nur Samsu

Citations in the corpus

• Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment (2021, methodology): “Based on the EMPA-REG outcome study (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin also inhibits the progression of kidney disease, which is characterized by a 39% reduction in worsening nephropathy or cardiovascular death [155].”
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017, neutral): “New England Journal of Medicine, 377(7), 644-657.”